Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.48 |
| ▸ | ITGAV | P06756 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tiropramide SCHEMBL2255455 | 0.99 | LMNA (0.53) | LMNATDP1HSD17B10ITGB3ITGA2B | |
| Tiropramide SCHEMBL25414380 | 0.98 | LMNA (0.53) | LMNATDP1HSD17B10ITGB3ITGA2B | |
| Tiropramide SCHEMBL25414231 | 0.98 | LMNA (0.53) | LMNATDP1HSD17B10ITGB3ITGA2B | |
| Sevopramide SCHEMBL2110566 | 0.95 | HRH3 (0.55) | LMNATDP1HSD17B10ITGB3ITGA2B | |
| SCHEMBL7300651 | 0.89 | ITGB3 (0.66) | LMNAITGB3ITGA2BGAARAB9A | |
| SCHEMBL11826987 | 0.87 | ITGB3 (0.58) | ITGB3ITGA2BKMT2AMEN1GAA | |
| SCHEMBL11778188 | 0.84 | ITGB3 (0.53) | ITGB3ITGA2BKMT2AMEN1GAA | |
| SCHEMBL27889054 | 0.82 | LMNA (0.65) | LMNATDP1HSD17B10KMT2AMEN1 | |
| SCHEMBL27889052 | 0.82 | LMNA (0.65) | LMNATDP1HSD17B10KMT2AMEN1 | |
| SCHEMBL11782109 | 0.82 | ITGB3 (0.50) | ITGB3ITGA2BKMT2AMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11534375-B2 | Solvent-free method of encapsulating a hydrophobic active | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-27 | — | — | US | claimed |
| US-20200179248-A1 | SOLVENT-FREE METHOD OF ENCAPSULATING A HYDROPHOBIC ACTIVE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-06-11 | — | — | US | claimed |
| WO-2018182509-A1 | SOLVENT-FREE METHOD OF ENCAPSULATING A HYDROPHOBIC ACTIVE | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-10-04 | — | — | WO | claimed |
| EP-2956450-B1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | UNIV MUENCHEN TECH (DE) | 2018-07-25 | — | — | EP | claimed |
| US-20150376164-A1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2015-12-31 | — | — | US | claimed |
| EP-2956450-A1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | Technische Universität München (DE) | 2015-12-23 | — | — | EP | claimed |
| WO-2014125084-A1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | Technische Universität München (DE) | 2014-08-21 | — | — | WO | claimed |
| US-20130006351-A1 | POLYMER COATINGS CONTAINING DRUG POWDER OF CONTROLLED MORPHOLOGY | MICELL TECHNOLOGIES, INC. (US) | 2013-01-03 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| EP-0687172-B1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | PHARMACIA AB (SE) | 2002-12-04 | — | — | EP | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| US-6207178-B1 | STABLE SUSPENSION | KABI PHARMACIA AB (SE) | 2001-03-27 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| US-5785976-A | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof | PHARMACIA & UPJOHN AB (SE) | 1998-07-28 | — | — | US | claimed |
| US-5770221-A | HIGH AND LOW MOLECULAR WEIGHT POLYISOBUTYLENE | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 1998-06-23 | — | — | US | claimed |
| EP-0687172-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | Pharmacia & Upjohn Aktiebolag (SE) | 1995-12-20 | — | — | EP | claimed |
| WO-1994020072-A1 | SOLID LIPID PARTICLES, PARTICLES OF BIOACTIVE AGENTS AND METHODS FOR THE MANUFACTURE AND USE THEREOF | PHARMACIA AB (SE) | 1994-09-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376164-A1 | HYDROXYINDALPINE DERIVATIVES AND THEIR MEDICAL USE | HTR5A, HTR4, HTR6 | LMNA 3091/4885TDP1 2527/4885HSD17B10 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.